DAXI 80 U

Revance Therapeutics, Inc. · Phase 2 active Biologic

At a glance

Generic name	DAXI 80 U
Sponsor	Revance Therapeutics, Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DAXI 80 U CI brief — competitive landscape report
DAXI 80 U updates RSS · CI watch RSS
Revance Therapeutics, Inc. portfolio CI